Ask five vendors how big the US aesthetics market is and you will get five different answers, and not answers that are close to each other. Depending on which report a sales VP is handed, the total addressable market is somewhere between $6 billion and $49 billion. That is not a rounding difference. It is an eightfold spread on the single number that gets used to justify sales force sizing, territory design, and board-level growth targets.
Why the estimates are so far apart
Part of the spread comes from scope: some estimates count only surgical procedures, some only devices, some the full consumer spend including skincare and injectables. But a large part of it comes from a more basic problem: nobody agrees on how many practices actually exist. Published practice counts swing from roughly 10,500, the AmSpa association estimate, to roughly 48,500 from web-scraping-based data providers. Both numbers come from real methodologies. Both are measuring different things.
AmSpa's number reflects association membership and reported industry participation, a real but incomplete slice. Scraper-based counts tend to overcount by picking up duplicate listings, defunct businesses, and non-practice entities like product distributors caught in a broad web crawl.
Our number: $41.7 billion, bottom-up
We built our estimate the other direction: start from our verified census of 48,198 US aesthetic practices, and for each one, estimate revenue from what it actually advertises, its treatment menu, device stack, and market position, rather than starting from a national survey and dividing it down.
That bottom-up approach lands at $41.7 billion for the US aesthetics market. It is a method, not a guess: revenue tiers built from advertised treatments, device ownership, and practice scale, summed across every verified practice rather than extrapolated from a sample.
Revenue concentration inside that number is sharp. The top 10% of practices by our scoring account for 54.4% of total revenue. Surgical practices, only about 10% of all practices, account for 41% of revenue, roughly $17.2 billion, a category that punches far above its practice count because of average transaction size.
Why claims data cannot fix this
The legacy alternative, Medicare and insurance claims data, is 6 or more months old by the time it is usable and is structurally blind to cash-pay aesthetics, which is most of the category. It was never built to answer "how big is the elective aesthetics market," and it cannot be patched into answering it now.
What this means for a rep or manufacturer
A $6B estimate and a $49B estimate cannot both be informing the same sales force sizing decision, but in practice they often do, because nobody checks the methodology behind the number they were handed. A bottom-up count, tied to actual verified practices and actual advertised revenue drivers, is the only version of this number that a manufacturer can defend and act on with confidence.
Want this cut for your territory? Book a demo.